Estimates of the proportion of older white men who would be recommended for pharmacologic treatment by the new US national osteoporosis foundation guidelines

Journal of Bone and Mineral Research

Volumn 25, Issue 7, 2010, Pages 1506-1511

  Donaldson, Meghan G ^a   Cawthon, Peggy M ^a   Lui, Lily Y ^a   Schousboe, John T ^b   Ensrud, Kristine E ^c   Taylor, Brent C ^c   Cauley, Jane A ^d   Hillier, Teresa A ^e   Dam, Thuy T ^f   Curtis, Jeff R ^g   Black, Dennis M ^h   Bauer, Douglas C ^h   Orwoll, Eric S ⁱ   Cummings, Steven R ^a,h  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF PITTSBURGH   (United States)

^e CENTER FOR HEALTH RESEARCH   (United States)

^f Och Spine at New York Presbyterian Hospitals   (United States)

^g The University of Alabama at Birmingham   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Bone density; Epidemiology; Guidelines; Men; Osteoporosis; Treatment

Indexed keywords

AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; CAUCASIAN; CONTROLLED STUDY; FEMUR NECK; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; OSTEOPOROSIS; PHARMACEUTICAL CARE; PRACTICE GUIDELINE; SPINE; TREATMENT PLANNING; UNITED STATES; VERTEBRA FRACTURE;

AGED; BONE DENSITY; BONE DISEASES, METABOLIC; FEMUR NECK; FRACTURES, SPONTANEOUS; GUIDELINES AS TOPIC; HUMANS; MALE; MIDDLE AGED; NUTRITION SURVEYS; OSTEOPOROSIS; OSTEOPOROTIC FRACTURES; SPINAL FRACTURES; UNITED STATES;

EID: 77954724087     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1002/jbmr.55     Document Type: Article

References (18)

1. National Osteoporosis Foundation. Clinician's Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation, 2008.
2. World Health Organisation. FRAX: WHO Fracture Risk Assessment Tool. Geneva: WHO, 2008.
3. Cummings SR, Cawthon PM, Ensrud KE, Cauley JA, Fink HA, Orwoll ES. BMD and risk of hip and nonvertebral fractures in older men: a prospective study and comparison with older women. J Bone Miner Res. 2006;21:1550-1556.
4. Fink HA, Blackwell TL, Taylor BC, et al. Distribution and rate of clinical fracture in older men without osteoporosis: the Osteoporotic Fractures in Men Study (MrOS). J Bone Miner Res. 2008; 23:S79.
5. Donaldson M, Cawthon P, Lui L, et al. Estimates of the proportion of older white women who would be recommended for pharmacologic treatment by the new US National Osteoporosis Foundation guidelines. J Bone Miner Res. 2010.
6. Orwoll E, Blank JB, Barrett-Connor E, et al. Design and baseline characteristics of the Osteoporotic Fractures in Men Study (MrOS): a large observational study of the determinants of fracture in older men. Contemp Clin Trials. 2005;26:569-585.
7. Blank JB, Cawthon PM, Carrion-Petersen ML, et al. Overview of recruitment for the Osteoporotic Fractures in Men Study (MrOS). Contemp Clin Trials. 2005;26:557-568.
8. Looker AC, Wahner HW, Dunn WL, et al. Updated data on proximal femur bonemineral levels of US adults. Osteoporos Int. 1998;8:468-489.
9. Kanis JA, Johnell O, Oden A, Johansson H, McCloskey E. FRAX and the assessment of fracture probability in men and women from the UK. Osteoporos Int. 2008;19:385-397.
10. Richards JB, Leslie WD, Joseph L, et al. Changes to osteoporosis prevalence according to method of risk assessment. J Bone Miner Res. 2007;22:228-234.
11. Tosteson AN, Melton LJ 3rd, Dawson-Hughes B, et al. Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int. 2008;19:437-447.
12. MacLean C, Newberry S, Maglione M, et al. Systematic review: comparative effectiveness of treatments to prevent fractures in men and women with low bone density or osteoporosis. Ann Intern Med. 2008;148:197-213.
13. Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000;343:604-610.
14. Ringe JD, Dorst A, Faber H, Ibach K. Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study. Rheumatol Int. 2004;24:110-113.
15. Ringe JD, Faber H, Farahmand P, Dorst A. Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study. Rheumatol Int. 2006;26:427-431.
16. Boonen S, Orwoll ES, Wenderoth D, Stoner KJ, Eusebio R, Delmas PD. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study. J Bone Miner Res. 2009;24:719-725.
17. Orwoll ES, Scheele WH, Paul S, et al. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res. 2003;18:9-17.
18. Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP. Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab. 2000;85:3069-3076.